Pregnancy and breastfeeding: as an investigational medicine, retatrutide has not been studied in pregnancy or breastfeeding
GLP-1 RAs showed trends toward improvements in endocrine and metabolic, cardiovascular, renal, and respiratory outcomes, cognitive function, with a potential reduction in fracture risk and all-cause mortality in certain populations
The approval allows for earlier intervention and treatment with Rybelsus in adults with type 2 diabetes, when previously it was not approved as an initial (first-line) treatment option
Use this page as research context, not as a treatment plan
they are neurochemical and physiological changes mediated by semaglutide's binding to specific GLP-1 receptor sites in your brain and gastrointestinal tract
These stimuli will also stimulate brain microglia and trigger the NLRP3 inflammasome to release IL-1 and IL-18 (Troubat et al., 2021)